Provectus Pharmaceuticals (PVCT) Moves Clinical Program against Metastatic Melanoma Forward, Article Posted on BeaconEquity.com
Provectus adds fourth center to phase 2 clinical trial of PV-10 and announces first peer-reviewed publication on PV-10 in Melanoma Research.
(EMAILWIRE.COM, October 21, 2008 ) DALLAS, Texas - BeaconEquity.com announces the publication of “Provectus Pharmaceuticals (PVCT) Moves Clinical Program against Metastatic Melanoma Forward.”
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m - Click on News and Commentary
In the article the author writes:
"Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has opened a new front on the war against cancer. Provectus' advanced therapies are designed to target and destroy the deadliest cancers – melanoma, liver and breast – while eliminating side effects.”
Provectus recently announced it expects to expand study of its phase 2 clinical trial for melanoma treatement:
“Pushing its fight against the most aggressive and deadly form of skin cancer, Provectus has begun recruiting for its phase 2 clinical trial of the company's lead oncology agent PV-10 at a fourth major center, now covering Adelaide, Australia, in addition to Sydney and Brisbane, Australia, as well as M.D. Anderson in Houston, Texas. Over the next several months, the company expects to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States.”
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting:
http://www.beaconequity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m - Click on News and Commentary
In the article the author writes:
"Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has opened a new front on the war against cancer. Provectus' advanced therapies are designed to target and destroy the deadliest cancers – melanoma, liver and breast – while eliminating side effects.”
Provectus recently announced it expects to expand study of its phase 2 clinical trial for melanoma treatement:
“Pushing its fight against the most aggressive and deadly form of skin cancer, Provectus has begun recruiting for its phase 2 clinical trial of the company's lead oncology agent PV-10 at a fourth major center, now covering Adelaide, Australia, in addition to Sydney and Brisbane, Australia, as well as M.D. Anderson in Houston, Texas. Over the next several months, the company expects to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States.”
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting:
http://www.beaconequity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Contact Information:
Beacon Equity Research
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity Research
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Press Release Keywords:
stock market, investing, investment ideas, market activity, small caps, micro caps, search engines, technology stocks, blue chips, marketing solutions, beaconequity.com, provectus pharmaceuticals
stock market, investing, investment ideas, market activity, small caps, micro caps, search engines, technology stocks, blue chips, marketing solutions, beaconequity.com, provectus pharmaceuticals
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |